Indian Pharmaceutical Market Obtains Growth Of 7.1% To Rs.9,754 Crore In February 2018

The Indian Pharmaceutical Market (IPM) has enlisted growth of 7.1 percent development during the month of February 2018 to Rs.9,754 crore, which is lower than the development of January 2018.

As per AIOCD AWACS report, Indian companies growth was only 6.6 percent when compared with MNC growth of 9.2 percent during February 2018.

The volumes of GDs enhanced by 5.6 percent but price component has dragged the market development. FDC related market achieved development of 21.7 percent while non-FDC market demonstrated a development of 7.6 percent.

The IPM development was only 5.4 percent during April-February 2018 because of the effect of implementation of GST.

Among the top 10 corporates, Lupin has the highest growth at 15 percent followed by Abbott at 12.5 percent and Alkem at 12.2 percent. Out of top 50 corporates, 42 corporate achieved positive development of IPM during February 2018. Among the best 50 corporate, Hetero has the highest growth of 30.1 percent followed by Allergan growing at 26.6 for percent and MSD at 25.5 percent. Abbott HC registered a development of 14.7 percent and Abbott India at 19.4 percent. Sun Portfolio has demonstrated a development of 8.9 percent, while Ranbaxy has slowed down to 1.2 percent for February 2018.

Indian Pharmaceutical Market Obtains Growth Of 7.1% To Rs.9,754 Crore In February 2018

From the regional point of view, 28 regions have posted positive development for the month of February 2018. Haryana clocked the highest development at 20.8 percent took after by South Rajasthan at 16.31 percent and North Karnataka at 14.63 percent.

Among the molecules, amoxicillin plus clavulanic acid market moved up by 13.5 percent during February 2018 to Rs.171.7 crore and glimepiride plus metformin market up by 2.4 percent to Rs 163.9 crore. Azilsartan plain market valued at Rs.62.7 crore on MAT basis, sofosbuvir and its combination market have reached Rs.599.7 crore. The luliconazole market reached Rs.255.4 crore on MAT premise and tenengliptin and its combinations have crossed Rs.627.3 crore.

The market of paracetamol plain went up by 10.9 percent, nonetheless, plain atorvastatin market declined by 4.2 percent. Probiotic microbes market demonstrated a double-digit growth of 15 percent, pantoprazole plain has posted a growth of 3.9 percent, montelukast plus to levocetirizine also achieved double-digit growth of 20.7 percent. Voglibose plus to metformin plus glimepiride moved up by 12.8 percent. Plain azithromycin market grabbed growth of 15.3 percent.

Among the brands, Mixtard stands out with 36 crores followed by Glycomet GP at Rs 34 crore, Spasmoproxyvon plus at Rs.38 crore, Lalnntus at Rs.32 crore a Galvus met at Rs.32 crore and Liv 52 at Rs.27 crore. Janumet reached Rs.30 crore during February 2018.

Few brands have gained ranks on MAT basis include Clavam, Cilacar, Udiliv, Ultrace, Duolin, Gluconorm G, Betnovate, etc. During February 2018, within the VMS category, there have been 6 brands launched for the month of February 2018 and that in cardiac there have been 13 brands and 15 brands in derma segment.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

sixteen + 20 =